Compare DraftKings Inc (DKNG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Sanofi SA — how do they compare? DraftKings Inc trades at $19.57 (market cap $9.86B), while Sanofi SA trades at $40.02 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 9.7× DraftKings Inc's market cap, and Sanofi SA pays a 6.01% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Sanofi SA for 94 Days on average.
| DKNG | SNY | |
|---|---|---|
Market Cap | $9.86B | $95.18B |
Volume | 16,584,596 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $52.34 |
52-Week Low | $18.59 | $39.51 |
Typical Hold Time | 55 Days | 94 Days |
Enterprise Value | $10.80B | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.15, down 3.04% and near its 52-week low of $18.95. The stock is technically bearish with weak moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue grew to $6.05B in 2025 with a slight net profit of $3.71M, but recent quarters show earnings misses. The company is investing in prediction markets and maintains a $1B EBITDA target for 2026.
Despite a high valuation (P/E 246.33) and recent price decline, 75% of analysts rate DKNG a Buy with a $33.13 consensus target. Key risks include competitive pressure, regulatory uncertainty, and the stock's sensitivity to growth expectations. The path to sustained profitability and margin expansion remains critical for investor confidence.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
